Avacta Group Gelecekteki Büyüme
Future kriter kontrolleri 1/6
Avacta Group's earnings are forecast to decline at 0.4% per annum while its annual revenue is expected to grow at 14.3% per year. EPS is expected to grow by 8% per annum. Return on equity is forecast to be -73.3% in 3 years.
Anahtar bilgiler
-0.4%
Kazanç büyüme oranı
8.0%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 37.3% |
| Gelir büyüme oranı | 14.3% |
| Gelecekteki özkaynak getirisi | -73.3% |
| Analist kapsamı | Low |
| Son güncelleme | 11 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Is Avacta Group (LON:AVCT) Using Debt Sensibly?
Oct 29
Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up
Sep 05Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet
Jun 21Investors Give Avacta Group Plc (LON:AVCT) Shares A 26% Hiding
Feb 23Getting In Cheap On Avacta Group Plc (LON:AVCT) Is Unlikely
Aug 05Would Avacta Group (LON:AVCT) Be Better Off With Less Debt?
Jun 22We're Hopeful That Avacta Group (LON:AVCT) Will Use Its Cash Wisely
Oct 20This Is The Reason Why We Think Avacta Group Plc's (LON:AVCT) CEO Deserves A Bump Up To Their Compensation
Jun 22Avacta Group (LON:AVCT) Is In A Good Position To Deliver On Growth Plans
Jun 20Avacta Group Plc (LON:AVCT) Insiders Have Been Selling
Feb 18Companies Like Avacta Group (LON:AVCT) Are In A Position To Invest In Growth
Jan 23
Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 33 | -25 | -31 | N/A | 2 |
| 12/31/2025 | 28 | -34 | -33 | -24 | 3 |
| 12/31/2024 | 25 | -35 | -36 | -24 | 3 |
| 6/30/2024 | 23 | -26 | -21 | -19 | N/A |
| 3/31/2024 | 23 | -25 | -18 | -17 | N/A |
| 12/31/2023 | 23 | -25 | -16 | -15 | N/A |
| 9/30/2023 | 20 | -32 | -16 | -15 | N/A |
| 6/30/2023 | 16 | -40 | -16 | -15 | N/A |
| 3/31/2023 | 13 | -38 | -16 | -16 | N/A |
| 12/31/2022 | 10 | -37 | -17 | -16 | N/A |
| 9/30/2022 | 8 | -31 | -19 | -18 | N/A |
| 6/30/2022 | 7 | -25 | -21 | -20 | N/A |
| 3/31/2022 | 5 | -26 | -21 | -20 | N/A |
| 12/31/2021 | 3 | -26 | -22 | -21 | N/A |
| 6/30/2021 | 2 | -20 | -18 | -16 | N/A |
| 3/31/2021 | 2 | -18 | -15 | -14 | N/A |
| 12/31/2020 | 2 | -16 | -12 | -11 | N/A |
| 6/30/2020 | 5 | -12 | -9 | -8 | N/A |
| 3/31/2020 | 4 | -12 | -10 | -9 | N/A |
| 12/31/2019 | 4 | -11 | -11 | -9 | N/A |
| 7/31/2019 | 4 | -10 | -10 | -8 | N/A |
| 4/30/2019 | 3 | -10 | -9 | -6 | N/A |
| 1/31/2019 | 2 | -10 | -7 | -5 | N/A |
| 10/31/2018 | 3 | -9 | -8 | -5 | N/A |
| 7/31/2018 | 3 | -9 | -8 | -5 | N/A |
| 4/30/2018 | 3 | -8 | N/A | -6 | N/A |
| 1/31/2018 | 3 | -7 | N/A | -6 | N/A |
| 10/31/2017 | 3 | -7 | N/A | -5 | N/A |
| 7/31/2017 | 3 | -6 | N/A | -4 | N/A |
| 4/30/2017 | 3 | -6 | N/A | -4 | N/A |
| 1/31/2017 | 2 | -6 | N/A | -5 | N/A |
| 10/31/2016 | 2 | -5 | N/A | -4 | N/A |
| 7/31/2016 | 2 | -5 | N/A | -4 | N/A |
| 4/30/2016 | 2 | -5 | N/A | -3 | N/A |
| 1/31/2016 | 2 | -5 | N/A | -3 | N/A |
| 10/31/2015 | 2 | -5 | N/A | -3 | N/A |
| 7/31/2015 | 2 | -5 | N/A | -3 | N/A |
| 4/30/2015 | 2 | -4 | N/A | -2 | N/A |
| 1/31/2015 | 2 | -3 | N/A | -2 | N/A |
| 10/31/2014 | 2 | -2 | N/A | -1 | N/A |
| 7/31/2014 | 2 | -1 | N/A | -1 | N/A |
| 4/30/2014 | 2 | -1 | N/A | -1 | N/A |
| 1/31/2014 | 2 | -1 | N/A | -1 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: AVCT is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: AVCT is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: AVCT is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: AVCT's revenue (14.3% per year) is forecast to grow faster than the UK market (3.6% per year).
Yüksek Büyüme Geliri: AVCT's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: AVCT is forecast to be unprofitable in 3 years.